Mizuho Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY)
October 2, 2024 5:37 AM EDTGoldman Sachs analyst Corinne Jenkins reiterated a Sell rating and $28.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY)
The analyst comments "HRMY hosted its Investor Day (10/1) where the focus was on its three neurology franchises, including within (i) sleep/wake, (ii) neurobehavioral, and (iii) epilepsy verticals. The sleep/wake focus was... More
